Business
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $16.6 million Reaffirmed 2023 expected total
About this update from Ultragenyx Pharmaceutical Inc.
[{"type":"text","content":"Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million Presented positive updates on three lead clinical programs at Analyst Day in October NOVATO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended September 30, 2023 and provided its financial guidance for the year. \"We're in a strong financial position due to growing demand for our commercial products, completion of our recent offering, and our disciplined expense and portfolio management,\" said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. \"We've also made significant progress on our key clinical programs and highlighted new, interim data from UX143 for osteogenesis imperfecta, GTX-102 for Angelman syndrome, and UX701 for Wilson Disease at our Analyst Day in October demonstrating promising therapeutic potential in these larger indications with further updates to come in 2024.\" Third Quarter 2023 Selected Financial Data Tables and Financial Results Revenues (dollars in thousands), (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022Crysvita Product sales$19,200 $13,184 $57,318 $34,980 Royalty revenue 35,160 — 64,221 — Non-cash royalty revenue 20,543 5,373 42,695 15,634 Revenue in profit-share territory — 51,348 69,705 148,121 Total Crysvita revenue 74,903 69,905 233,939 198,735 Dojolvi 16,553 13,274 47,347 39,200 Mepsevii 5,633 6,045 22,552 15,839 Evkeeza 963 — 1,540 — Daiichi Sankyo — 1,479 1,479 6,207 Total revenues$98,052 $90,703 $306,857 $259,981 Total RevenuesUltragenyx reported $98.1 million in total revenue for the third quarter 2023, which represents 8% growth compared to the third quarter 2022. Third quarter 2023 Crysvita product sales, primarily in Latin America, were $19.2 million, which represents 46% growth compared to the same period in 2022 and 14% growth over the second quarter 2023. Third qu...